, and we would like to respond to their important points.
First, we concur that metformin should be temporarily discontinued in patients with conditions that predispose to acute kidney injury (AKI). Although this is not consistently recommended by regulatory bodies and guidelines 3, 4 , the studies by Connelly et al. and Bell et al. provide much-needed evidence for the potential toxicity of metformin in this context 5, 6 . Second, we concur that crude incidence rates of lactic acidosis may differ across studies that have heterogeneous patient populations. However, large observational studies using clinical databases may not accurately estimate the real-world incidence of metforminassociated lactic acidosis (MALA), particularly if ascertained using blood lactate levels ordered at the discretion of clinicians (instead of using a strict protocol for measurement among all study participants) or by diagnostic codes, in several ways 4, 7, 8 : first, eligibility criteria that requires patients to have one lactate measurement for inclusion may miss patients with elevated levels of lactate that aren't measured; second, metformin users may undergo more frequent lactate measurement than non-users, overestimating the risk of MALA; and third, the risk of MALA could conversely be underestimated owing to confounding by indication, as metformin users appeared to be healthier than non-users in both the Connelly et al. and Bell et al. studies 5, 6 . Third, regarding the absence of a new-user design, we agree that the ability of the study by Bell et al. to follow the majority of patients over an extended period with prescribing data from all pharmacies in the Tayside region is a major strength that mitigates potential survivor bias.
Fourth, we concur that the findings of 'ever' versus 'never' metformin use and risk of AKI may potentially be explained by confounding factors (that is, metformin as a marker for coexisting comorbidities). However, using the summary of table 2 in the original study (of patient characteristics stratified by time-updated metformin exposure status) as a gauge for the distribution of characteristics among metformin 'ever' versus 'never' users, there appears to be a tendency towards metformin prescription among healthier patients.
Finally, we acknowledge that there is widespread debate regarding the use of metformin in patients with chronic kidney disease (CKD), including the precise threshold at which this medication should be restricted 4, [7] [8] [9] [10] [11] [12] . However, patients with CKD have a greater, often unanticipated, susceptibility to AKI and a lower underlying reserve of renal function when AKI occurs 8, 13 . Furthermore, a large proportion of patients with CKD have AKIpredisposing conditions (for example, infection and/or sepsis, congestive heart failure and myocardial infarction) that further elevate their risk of MALA 14 . It is worth mentioning that one study, cited by the investigators in their correspondence, showed that there was a trend towards higher risk of acidosis and serious infection among metformin users with an estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m 2 (REFS 3, 15) and that another study 16 excluded patients with CKD (serum creatinine ≥1.5 mg/dl) or serious medical illness. Moreover, the high mortality rate from MALA and the multitude of alternative anti-diabetic pharmacotherapies available calls into question whether a small risk of metformin justifies its benefit. Although a recent rigorous systematic review concluded that limited evidence suggests that metformin does not substantially affect lactate levels when eGFR is >30 ml/min/1.73 m 2 and that a consistent link between metformin and lactic acidosis was not observed across available evidence 7 , further studies, including randomized controlled trials that test the tolerability and effectiveness of metformin in CKD and the precise eGFR threshold above which metformin is safe, are urgently needed.
